

# Data Science in the Pharmaceutical Industry

**Driving Innovation through Insights** 

Dr James Black, Director, Insights Engineering Pharma Development Data Sciences German Data Science Days | 2023-03-09



# **Table of Contents**

Data science across the Roche Group

The diversity of data science across drug development lifecycles

Examples of data science in late stage

A snapshot of data science in our team in 2023




# **Roche in numbers**






# **Data science across Roche divisions**







# $\bigcirc$

# The diversity of data science across drug development lifecycles

### **Discovery**

0

Can I predict toxicity for a molecule structure?

How does the tumour genetic fingerprint (NGS) change after exposure to X and Y?

What is the relationship between X and Y in published abstracts?

## **Early development**

What is the ideal dose?

Is there a multiplicative benefit of combining mechanism X and Y for condition Z?

Is there a companion diagnostic to identify patients that would benefit the most?

### Late stage

What is the efficacy of our drug against standard of care?

What is the safety profile?

What portfolio of evidence is needed to show how this drug performs across different patients?

## Commercial

What are the treatment patterns across different markets?

What is the value of our drug across markets?

What are the trends in standard of care, and what KoLs are key drivers of care patterns?

Research and early development

Product development

Product strategy



# **Ex.1: External controls**




Randomised clinical trials are the gold standard for causal inference, but they are slow, expensive and tightly scoped to a specific hypothesis

Can we leverage the routinely collected data from EHR and claims, across millions of patients, to improve our evidence portfolio?

# **External controls 101**


#### Randomised clinical trial

Gold standard for treatment effect.



## Adjustment


Adjust and estimate effect in one step, e.g. a retrospective cohort study.



for known confounders

## Matching and weighting


Includes propensity scores.



#### $\vdash$

# Applying inclusion/exclusion criteria






# An example inc/exc attrition for a 2 LoT+ analysis

Starting with 6,012 patients in our real world database with the same disease and >1 LoT, we drop to 187 that meet real world *approximations* of the inclusion and exclusion criteria



# **Imbalance pre-analysis**






0

Standardised mean difference of baseline characteristics comparing real world control to single arm trial

Analysing our populations as-is would be likely to lead to bias.

# External controls: an area of active research



0

# Ex.2: The RAAD Challenges

0





# Roche Advanced Analytics Data (RAAD) Challenges

# **RAAD Challenge 1.0**

Predict the probability that a patient will be alive at 1 year after 1L treatment initiation, using all the patient data available up to the start of 1L treatment.



#### Data:

9,500 patients' across train and test from across seven different cancer types were used to train the models.



#### Participation:

500+ Roche employees, 132 teams, 28 sites

## RAAD Challenge 2.0

Predict response in a new drug and indication combination using training data containing either that drug in a different indication, or that indication with other drugs



#### Data:

6,000 patients across train and test from historical trials



#### Participation:

500+ Roche employees, 141 teams, 38 sites

RAAD Challenge 3.0 judging was last Friday!



# Data-Centricity: clinico-genomic feature library



# **Hackathon tasks**

With a fixed prediction model, enrich the training data and create 10 features that improve prediction on the test data.





# Benefit to Roche & our Patients

This challenge focuses our attention not on the model, but on the preparation of data for modeling, and will help to develop a rich catalog of features enabling future researchers to develop more impactful insights and products (e.g. to support clinical decision support at point of care, enhanced patient segmentation for clinical trials etc).

# Data-Centricity: clinico-genomic feature library






Vitals



0



Demographics







Prediction target is time till death



96,686 patients



118 variables



58,066 events



744 MBs of data



93,673,017 data points



Train - 60%



Leaderboard - 20%



Test - 20%





# Data science in our team in 2023





#### -

# Being multilingual is the new-norm





0





We focus on R-backbone for analytics, and python for tooling, but there is a continued growth in other languages and technologies that we leverage in the pursuit of constantly doing things 'better'


5 years ago Today



# Data products, in addition to static insights, is now the new normal







# We have more of a focus on re-use, and open source




Example R packages our team work on.

In Feb 2023, our team of ~50 data scientists contributed at least one commit to 100 open source repositories, and 117 closed source repositories.

0

# An area of recent growth: Statistical Engineering

rconsortium.github.io/asa-biop-swe-wg







# Our first coursera course is now live!



Bridging general DS into clinical reporting DS



Statistical Programming, Statistical engineering & RWE courses coming



go.roche.com/course

